The efficacy and safety of the combination of camrelizumab and albumin-bound paclitaxel in second-line treatment of advanced gastric cancer
Objective To observe the effect of the combination of camrelizumab and albumin-bound paclitaxel in second-line treatment of advanced gastric cancer.Methods 80 patients with advanced gastric cancer were divided into a control group and a combination group using a random number table method,each consisting of 40 patients.The control group was treated with camrelizumab injection,while the combination group was treated with camrelizumab combined with albumin-bound paclitaxel second-line therapy.The clinical efficacy,and tumor markers before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the combination group was 95.00%,which was higher than 77.50% of the control group,and the difference was significant(P<0.05).After treatment,the combination group had alpha-fetoprotein of(26.45±5.52)μg/L,carcinoembryonic antigen of(7.29±2.12)μg/L,prostate-specific antigen of(38.46±7.12)μg/L,and carbohydrate antigen 19-9 of(6.20±1.28)U/ml,which were lower than(35.42±5.67)μg/L,(10.44±3.18)μg/L,(9.88±2.20)μg/L and(46.76±7.33)U/ml in the control group,and the difference was significant(P<0.05).After treatment,the incidence of adverse reactions in the combination group was 25.00%,which was higher than 20.00% in the control group,but there was no significant difference(P>0.05).Conclusion The combination of camrelizumab and albumin-bound paclitaxel second-line therapy for advanced gastric cancer patients can regulate tumor marker levels,effectively improve clinical symptoms,and enhance clinical efficacy.At the same time,the adverse reactions are similar to those of a single medication method,showing a certain degree of safety,and is worthy of clinical application.
万方数据
维普
